Mission Bio, a leader in single-cell multiomic solutions for precision medicine, today announced the launch of a new single-cell capability that enhances our understanding of translocations (chromosomal rearrangements) in gene-edited therapies. Measuring predicted translocations along with on- and off-target editing at single-cell resolution can enable developers to design more efficient and safer therapeutics. Data being presented at the Annual American Society of Gene & Cell Therapy (ASGCT) Meeting further validates Tapestri’s translocation analysis for comprehensive characterization of genome-edited cells, which is crucial for the development of cell-based therapies like CAR-T cells and stem cell-based therapies.
